Back to Blog
Hims & Hers Partners With Eli Lilly to Offer Zepbound and Foundayo

Hims & Hers Partners With Eli Lilly to Offer Zepbound and Foundayo


Hims & Hers and Eli Lilly announced a partnership on November 6, 2026, giving eligible patients access to Lilly's weight-loss medicines through Hims' online consultation, prescribing, and home-delivery service.[1]

Zepbound and Foundayo help eligible adults lose weight and keep it off. Zepbound (tirzepatide) is a once-weekly injection; Foundayo (orforglipron) is a daily pill. Both are approved by the Food and Drug Administration (FDA) for adults with obesity, or overweight with a weight-related health condition, alongside a reduced-calorie diet and increased physical activity.[1]

Medication

Active ingredient

Format

Starting self-pay price

Zepbound

Tirzepatide

Weekly injection

$299 per month

Foundayo

Orforglipron

Daily pill

$149 per month

These are Lilly’s existing self-pay prices, rather than an exclusive Hims discount.[1] The drug price is not the full bill, however.

Hims requires a separate weight-loss membership

  • $39 for the first month, then $149 a month

  • This is billed apart from the medication and not FSA/HSA-eligible.[5]

  • A patient on Foundayo should expect roughly $298 a month at the starting dose after month one; a Zepbound patient roughly $448. Lilly’s figures are starting-dose prices, and the announcement does not break out costs at higher doses.[1]

How the Service Works

Hims & Hers connects patients with licensed healthcare professionals through online consultations. Patients submit their health history and treatment goals for a provider to review.[2]

The companies say prescribing decisions will remain independent. A provider must determine whether a medication is appropriate for the patient.[1]

Hims says its weight-loss membership includes 24/7 access to a care team, nutrition guidance, regular clinical check-ins, and an online weight-loss community.[1]

Hims & Hers' Expansion Into Weight-Loss Care

Hims launched in November 2017 at venture studio Atomic. The company identifies Andrew Dudum, Hilary Coles, Jack Abraham, and Joe Spector as its founders.[3] Dudum remains chief executive officer and previously co-founded Atomic Labs.[4]

Its early business focused on men's health, including hair loss and erectile dysfunction. Hers launched in 2018. Hims & Hers went public through a merger with a special-purpose acquisition company in 2021 and acquired Apostrophe and Honest Health that year. The company expanded its weight-loss offerings in 2023.[2]

Why Lilly held out for two years

Lilly spent 2025 building a direct-to-consumer channel, LillyDirect, with telehealth partners like Ro while pointedly excluding Hims. The reason was compounding. Hims began offering compounded GLP-1s in May 2024 and grew into the most visible seller of cheaper, non-FDA-approved copies of Novo Nordisk's semaglutide.

In June 2025, Lilly's chief financial officer said the company would only work with telehealth firms that agreed to stop selling copycat weight-loss drugs, which Bloomberg Law reported made a Hims deal unlikely. Hims had been openly courting Lilly since its Q1 2025 earnings call.

The pressure then came from regulators. In September 2025 the FDA sent Hims a warning letter over website claims that its compounded products contained the same active ingredient as Ozempic and Wegovy. In February 2026 the agency said it intended to restrict the GLP-1 ingredients used in mass-marketed compounded alternatives, and Hims was named directly, as the company disclosed in its Q2 2026 10-Q. Hims responded by shifting its U.S. weight-loss offering toward branded drugs and scaling compounding back to a limited role.

That shift produced a settlement and distribution deal with Novo Nordisk earlier this year, which brought branded Wegovy onto the Hims platform. The Lilly agreement follows the same template.

The Agreement's Compounding Commitment

Hims & Hers also said it has never offered compounded copies of Lilly's glucagon-like peptide-1 (GLP-1) medicines and committed not to offer them in the future. The commitment concerns Lilly's drugs.[1]

The announcement does not disclose financial terms between the companies.[1]

What to watch

  • Terms. No financial terms were disclosed. Whether Lilly is paying Hims for volume, Hims is buying at a discount, or neither, shapes how durable the partnership is.

  • Compounded semaglutide. Hims still offers it on a limited basis. If the FDA finishes the restriction it previewed in February, that line of business ends regardless of any Lilly agreement.

  • The Novo side. Hims now carries both companies' branded drugs. The next question is whether either manufacturer pushes for preferred placement, and whether that squares with the provider-independence language both deals contain.

  • Price. $299 for Zepbound and $149 for Foundayo are Lilly's list self-pay prices. Any movement there comes from Lilly's pricing strategy, not from Hims.

Sources

  1. Eli Lilly and Company and Hims & Hers Health, Inc. (2026, November 6). Lilly and Hims & Hers expand access to FDA-approved Lilly medicines. Eli Lilly release via PR Newswire. Read the partnership announcement.

  2. Hims & Hers. (Accessed November 7, 2026). About Hims: Modern Men's Healthcare. Hims. Company history and care process.

  3. Hims & Hers. (2020, October 1). Hims & Hers, a Multi-Specialty Telehealth Platform, to Become Publicly-Traded via Merger with Oaktree Acquisition Corp. Hims & Hers investor relations. Founders and public-market transaction announcement.

  4. Hims & Hers. (Accessed November 7, 2026). Executive Management: Andrew Dudum. Hims & Hers investor relations. Andrew Dudum's executive biography.

  5. Hims & Hers. (Accessed November 7, 2026). GLP-1 weight loss medications. Hims. https://hims.com/glp1. Membership fee, billing terms, and FSA/HSA eligibility.


Related Posts